Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in Hematol Oncol Clin North Am

Retrieve available abstracts of 17 articles:
HTML format



Single Articles


    February 2022
  1. MELLINGHOFF IK, Chang SM, Jaeckle KA, van den Bent M, et al
    Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms.
    Hematol Oncol Clin North Am. 2022;36:95-111.
    PubMed     Abstract available


    August 2021
  2. BROWN JR
    Chronic Lymphocytic Leukemia: So Much Progress, Still Challenges Ahead.
    Hematol Oncol Clin North Am. 2021;35:xiii-xiv.
    PubMed    


  3. SHADMAN M, Maloney DG
    Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.
    Hematol Oncol Clin North Am. 2021;35:847-862.
    PubMed     Abstract available


  4. SUN C, Wiestner A
    Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?
    Hematol Oncol Clin North Am. 2021;35:827-845.
    PubMed     Abstract available


  5. LAMPSON BL, Brown JR
    The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
    Hematol Oncol Clin North Am. 2021;35:807-826.
    PubMed     Abstract available


  6. THOMPSON MC, Mato AR
    Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Hematol Oncol Clin North Am. 2021;35:793-806.
    PubMed     Abstract available


  7. LASICA M, Tam CS
    Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
    Hematol Oncol Clin North Am. 2021;35:761-773.
    PubMed     Abstract available


  8. DING W
    The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.
    Hematol Oncol Clin North Am. 2021;35:739-759.
    PubMed     Abstract available


  9. CHERNG HJ, Jain N
    First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
    Hematol Oncol Clin North Am. 2021;35:725-738.
    PubMed     Abstract available


  10. VLACHONIKOLA E, Sofou E, Chatzidimitriou A, Stamatopoulos K, et al
    The Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical Implications.
    Hematol Oncol Clin North Am. 2021;35:687-702.
    PubMed     Abstract available


  11. NG A, Chiorazzi N
    Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic Leukemia.
    Hematol Oncol Clin North Am. 2021;35:665-685.
    PubMed     Abstract available


  12. THANGAVADIVEL S, Woyach JA
    Genomics of Resistance to Targeted Therapies.
    Hematol Oncol Clin North Am. 2021;35:715-724.
    PubMed     Abstract available


  13. LJUNGSTROM V, Baliakas P
    Prognostic and Predictive Implications of Cytogenetics and Genomics.
    Hematol Oncol Clin North Am. 2021;35:703-713.
    PubMed     Abstract available


    May 2021
  14. AL-SAWAF O, Seymour JF, Kater AP, Fischer K, et al
    Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?
    Hematol Oncol Clin North Am. 2021 May 15. pii: S0889-8588(21)00039.
    PubMed     Abstract available


    April 2021
  15. JAIN T, Rampal RK
    Accelerated and Blast Phase Myeloproliferative Neoplasms.
    Hematol Oncol Clin North Am. 2021;35:325-335.
    PubMed     Abstract available


    April 2020
  16. GARCIA JS
    Prospects for Venetoclax in Myelodysplastic Syndromes.
    Hematol Oncol Clin North Am. 2020;34:441-448.
    PubMed     Abstract available


    February 2020
  17. BALIGA S, Yock TI
    Pediatric Cancer.
    Hematol Oncol Clin North Am. 2020;34:143-159.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: